Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment

Oncology Letters

Volumn 5, Issue 6, 2013, Pages 1881-1888

  Toiyama, Yuji ^a   Fujikawa, Hiroyuki ^a   Koike, Yuki ^a   Saigusa, Susumu ^a   Inoue, Yasuhiro ^a   Tanaka, Koji ^a   Mohri, Yasuhiko ^a   Miki, Chikao ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Colorectal cancer; Lymph node number; Lymph node ratio; Stage migration

Indexed keywords

C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CLINICAL EVALUATION; COLORECTAL CANCER; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84876475075     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1308     Document Type: Article

References (37)

1. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330: 1136-1142, 1994.
2. Joseph NE, Sigurdson ER, Hanlon AL, et al: Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 10: 213-218, 2003.
3. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J and Virnig BA: Lymph node evaluation in colorectal cancer patients: a population-based study. J Natl Cancer Inst 97: 219-225, 2005.
4. Chang GJ, Rodriguez-Bigas MA, Skibber JM and Moyer VA: Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99: 433-441, 2007.
5. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349-1355, 1999.
6. Ratto C, Sofo L, Ippoliti M, et al: Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum 42: 143-158, 1999.
7. Caplin S, Cerottini J P, Bosman FT, Constanda MT and Givel JC: For patients with Dukes' B (TNM stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 83: 666-672, 1998.
8. Nelson H, Petrelli N, Carlin A, et al: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93: 583-596, 2001.
9. Prandi M, Lionetto R, Bini A, et al: Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymph-adenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235: 458-463, 2002.
10. Wong SL, Ji H, Hollenbeck BK, Morris AM, Baser O and Birkmeyer JD: Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 298: 2149-2154, 2007.
11. Noura S, Ohue M, Kano S, et al: Impact of metastatic lymph node ratio in node-positive colorectal cancer. World J Gastrointest Surg 2: 70-77, 2010.
12. Nakazaki H: Preoperative and postoperative cytokines in patients with cancer. Cancer 70: 709-713, 1992.
13. Nozoe T, Matsumata T, Kitamura M and Sugimachi K: Significance of preoperative elevation in serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335-338, 1998.
14. Nozoe T, Matsumata T and Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 23: 263-266, 2000.
15. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al: A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66: 2483-2487, 2006.
16. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y and Kusunoki M: C-reactive protein as a prognostic variable that refects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 49: 970-976, 2004.
17. Koike Y, Miki C, Okugawa Y, et al: Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98: 540-544, 2008.
18. Wiggers T, Arends J W, Schutte B, Volovics L and Bosman FT: A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61: 386-395, 1988.
19. Fletcher RH: Carcinoembryonic antigen. Ann Int Med 104: 66-73, 1986.
20. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA and Tangen C: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270: 943-947, 1993.
21. Tepper JE, O'Connell MJ, Niedzwiecki D, et al: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19: 157-163, 2001.
22. Joseph NE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21: 2912-2919, 2003.
23. Swanson RS, Compton CC, Stewart AK and Bland KI: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10: 65-71, 2003.
24. Bilimoria KY, Palis B, Stewart AK, et al: Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum 51: 154-161, 2008.
25. Leibl S, Tsybrovskyy O and Denk H: How many lymph nodes are necessary to stage early and advanced adenocarcinoma of the sigmoid colon and upper rectum? Virchows Arch 443: 133-138, 2003.
26. Horzic M and Kopljar M: Minimal number of lymph nodes that need to be examined for adequate staging of colorectal cancer - factors infuencing lymph node harvest. Hepatogastroenterology 52: 86-89, 2005.
27. AJCC Cancer Staging Manual. 6th edition. Springer, New York, 2002.
28. Le Voyer TE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21: 2912-2919, 2003.
29. Nitti D, Marchet A, Olivieri M, et al: Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 10: 1077-1085, 2003.
30. Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J and Storme G: The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 70: 225-230, 2004.
31. Berger AC, Watson JC, Ross EA and Hoffman JP: The metastatic/ examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 70: 235-240, 2004.
32. Inoue K, Nakane Y, Iiyama H, et al: The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 9: 27-34, 2002.
33. Berger AC, Sigurdson ER, LeVoyer T, et al: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 23: 8706-8712, 2005.
34. Lee HY, Choi HJ, Park KJ, et al: Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 14: 1712-1717, 2007.
35. Wang J, Hassett JM, Dayton MT and Kulaylat MN: Lymph node ratio: role in the staging of node-positive colon cancer. Ann Surg Oncol 15: 1600-1608, 2008.
36. Rosenberg R, Friederichs J, Schuster T, et al: Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg 248: 968-978, 2008.
37. Peng J, Xu Y, Guan Z, et al: Prognostic significance of the meta-static lymph node ratio in node-positive rectal cancer. Ann Surg Oncol 15: 3118-3123, 2008.